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Hemophagocytic syndrome (HPS) arises secondary to genetic, rheumatologic, neoplastic, and infectious causes. We discuss a
patient whose presentation was consistent with systemic infection but was discovered to have HPS of unknown etiology. The
presenting symptoms, as well as unremarkable malignancy and rheumatologic workups, led to the pursuit of an infectious cause,
but the patient was ultimately discovered to have an occult anaplastic large-cell lymphoma (ALCL). This case demonstrates the
diagnostic challenges that result from infectious mimicry in the context of HPS—ﬁrst, in distinguishing noninfectious HPS from
the systemic inﬂammation that can result from a widespread infectious process, second, in the identiﬁcation of the precipitating
causeofHPS.WhileevidenceofthesechallengeshasbeensuggestedbythelimitedliteratureonHPSandALCL,ourcaseillustrates
thediagnosticdilemmathatariseswhentissuebiopsydoesnotquicklyrevealanetiology.Itisimportantthatallphysiciansbeaware
that HPS can mimic infection and be prepared to redirect the workup when an infectious etiology for HPS cannot be identiﬁed.
1.Introduction
Hemophagocytic syndrome (HPS) is a rare, life-threatening
condition associated with signiﬁcant challenges in diagnosis
and management. HPS can be more speciﬁcally described
according to its association with a precipitating condition
in each patient. It is alternatively known as hemophagocytic
lymphohistiocytosis (HLH) when associated with a pri-
mary genetic disorder and macrophage-activation syndrome
(MAS)whenassociatedwitharheumatologicdisorder.Itcan
also occur secondary to malignancy (malignancy-associated
hemophagocytic syndrome, MAHS) or infection (infection-
associated hemophagocytic syndrome, IAHS). A physician
musthaveareasonableindexofsuspicionforHPSinpatients
with undiagnosed disease suggestive of systemic inﬂamma-
tion and must consider both infectious and noninfectious
etiologies of the syndrome once the diagnosis of HPS has
been made.
We report the case of a young adult presenting to our
institution with HPS that represented a challenge in the
diagnosis and search for an underlying etiology. This case
illustrates how the identiﬁcation of HPS can be delayed
when a primary infectious process is suggested by the
patient history, and how infectious mimicry can postpone
the consideration of malignancy as the primary cause once
HPS has been identiﬁed. Although the condition is rare,
it is important that physicians be prepared to consider the
diagnosis of HPS in cases where the infectious workup is
unexpectedly negative and be able to conduct a thorough
investigation for the underlying etiology when the syndrome
is identiﬁed.
2. Case Presentation
2.1. Patient Presentation and History. A 20-year-old male
from Mexico with no signiﬁcant past medical history2 Case Reports in Medicine
Figure 1: CT maxillofacial scan demonstrating extensive inﬂam-
matory changes of the left face without evidence of abscess. These
changes were later determined to be nonspeciﬁc inﬂammatory
changes resulting from ALCL-associated HPS.
presented with 3 months of left facial swelling and pain
associated with fevers, night sweats, unintentional weight
loss, myalgias, and arthralgias.
He had been evaluated and treated multiple times by
the emergency department, an inner city hospital, and an
outpatient dentist with several diﬀerent antibiotic regimens,
narcotic pain control, oral steroids, and drainage catheter
placement for a presumed dental abscess. His symptoms
improved slightly with these interventions but recurred after
the completion of each course of treatment. After his ﬁfth
admission at an outside hospital, he was transferred to our
university hospital for evaluation of fever of unknown origin
a n dw o r k u po fp r e s u m e ds e p s i s .
He denied visual changes, symptoms of upper or lower
respiratory infection, chest pain or palpitations, nausea,
vomiting, diarrhea, hematochezia, dysuria, exposure to
animals or insects, sick contacts, recent travel, or high-risk
behaviors for substance abuse or sexually transmitted infec-
tions. He had received all of his immunizations as a child in
Mexico. He denied family history of any illnesses.
2.2. Physical Examination. Upon transfer and admission to
our institution, his vital signs were within normal limits:
temperature of 98◦F, heart rate of 69 beats per minute, blood
pressure of 112/72, respiratory rate of 12 breaths per minute,
and oxygen saturation of 92% on room air. On exam, he
was noted to have nonmobile and tender left mandibular
swelling. His eye exam showed red scleral injection without
exudate and a grey-brown ring around the irises. Neck
exam revealed posterior left cervical lymphadenopathy that
was hard, ﬁxed, and painful. The remainder of the HEENT
exam was unremarkable. Lungs were clear to auscultation
bilaterally, and the cardiovascular exam was within normal
limits. The abdomen was soft, nontender, and nondistended.
Pulses were 2+ bilaterally, and the neurological exam was
nonfocal.
Figure 2: CT abdomen demonstrating extensive retroperitoneal
fat stranding. These changes were later determined on autopsy to
represent abdominal involvement of ALCL, which was present in
mesenteric and retroperitoneal lymph nodes.
2.3. Laboratory Evaluation and Radiologic Studies. Initial
laboratory evaluation was notable for hyponatremia (Na
133mmol/L, NL 135–145mmol/L), anemia (hemoglobin
9.5g/dL, NL 14.0–18.0g/dL; hematocrit 30%, NL 40.0–
52.0%), leukopenia (WBC 2.0 × 109/L, NL 4.0–10.0 ×
109/L), hypertriglyceridemia (284mg/dL, NL 30–150
mg/dL), and transaminitis (ALT 206U/L, NL 0–34U/L; AST
102U/L, NL 0–34U/L). Infectious disease evaluation on
admission included multiple blood and urine cultures that
were negative. A chest X-ray and computed tomography
(CT) imaging of the chest showed multiple bilateral
p u l m o n a r yn o d u l e so fu n c e r t a i ne t i o l o g ya sw e l la sar i g h t
lower lobe consolidation, paratracheal, mediastinal, and left
hilar nodes, and left axillary edema. CT of the abdomen and
pelvis showed bilateral pyelonephritis with enlarged spleen,
and a CT maxillofacial scan demonstrated inﬂammatory
changes of the face without evidence of abscess (Figure 1).
2.4. Treatment, Clinical Course, and Outcome. The patient
was started on broad-spectrum antibiotics, stress-dose ster-
oids, and IV ﬂuids, which resulted in hemodynamic stability
but persistent fevers. Repeat infectious disease workup, in-
cluding blood, urine, sputum, and fecal cultures, HIV test-
ing, PPD, VDRL, transthoracic echocardiography, and soft
tissue biopsy of the left mandible, was unremarkable.
A more thorough laboratory investigation was initiated.
Abnormalities included elevated LDH (1102U/L, NL 118–
232U/L), ferritin (13,500ng/mL, NL 18–370ng/mL), C-
reactive protein (64.6mg/L, NL 0.1–4.9mg/L), and erythro-
cytesedimentationrate(54mm/hr,NL0–20mm/hr).Repeat
CT scan revealed bilateral pleural eﬀusions, numerous
pulmonary nodules, and axillary, subpectoral, and retroperi-
toneal fat stranding (Figure 2). A PET scan demonstrated
several hypermetabolic lesions involving musculature and
fat stranding throughout the body, most likely related to a
systemic infectious or inﬂammatory process.
A liver biopsy was suggestive of drug reaction. Lung
nodule biopsy showed normal tissue in the lesions and no
evidence of infection or malignancy. Left mandibular soft
tissue biopsy showed necrosis and acute inﬂammation, but
noevidenceofinfectionormalignancy.Finally,bonemarrow
biopsy revealed extensive macrophage hemophagocytosis,
pathognomonic for hemophagocytic syndrome (Figure 3).Case Reports in Medicine 3
Figure 3: Bone marrow biopsy showing hemophagocytosis of an
erythrocyte by a macrophage, pathognomonic for hemophagocytic
syndrome.
The patient was recognized to have HPS and started on
IVIG and high-dose IV dexamethasone before transitioning
to a slow prednisone taper and cyclosporine. An extensive
search for an underlying rheumatic (ANA, ds DNA, anti-
MPO, anti-PR3, RF and CCF antibodies, c-ANCA, and
p-ANCA) and malignant etiology (ﬂow cytometry, T-cell
receptor rearrangement study, bone marrow, soft tissue,
and lung biopsies, PET scan) was unrevealing. No evidence
of malignancy was evident on any of the bone marrow
or soft tissue biopsy specimens. As a result, a working
diagnosis of infection-associated hemophagocytic syndrome
with an unknown primary infection was pursued. However,
an exhaustive infectious disease workup (including viral
hepatitis, EBV, Parvovirus, HSV, CMV, HHV-6, Coccidioides,
Trichinella, leishmaniasis, Cryptococcus, Aspergillus,h i s t o -
plasmosis, and acid-fast Bacilli)w a sn e g a t i v e .
Despite appropriate treatment for HPS, the patient
deteriorated and eventually expired from a massive GI bleed.
On autopsy, he was found to have occult anaplastic large-cell
lymphoma (ALCL; stage IV) involving lung, stomach, lower
GI tract, mesenteric lymph nodes, and spleen.
3. Discussion
3.1. Deﬁnition, Epidemiology, and Etiology of HPS. HPS
is a rare condition in which cytokine overstimulation of
macrophages results in overproliferation and hemophago-
cytosis in bone marrow and lymphoid tissue. It is charac-
terized by fever, splenomegaly, bicytopenia, hypertriglycer-
idemia or hypoﬁbrinogenemia, marked elevation in ferritin
(>500ng/mL), high concentration of soluble interleukin-2
receptor, low NK-cell activity, and macrophage hemophago-
cytosis on bone marrow biopsy [1, 2]. A patient must have
ﬁve conditions to meet criteria for diagnosis.
Primary HPS [3] is associated with genetic mutations,
while secondary HPS is attributed to infectious, rheuma-
tologic, or malignant causes resulting in massive cytokine
overstimulation. The disease is most commonly found in
children [4, 5]. Its prognosis is poor, and mortality has been
shown to approach 50% [6].
A comprehensive overview of case reports and case series
on a wide array of infectious processes associated with HPS
has previously been compiled [7] and demonstrates the
breadth of infectious etiologies that must be considered by
the infectious disease physician in a patient with HPS. Physi-
cians face several challenges in conducting the evaluation
for HPS in the context of a patient with a known infection.
An infectious process may precipitate both primary [8, 9]
and secondary forms of the condition, so it may not be
immediately obvious whether the disease has a genetic or
infectious primary cause. This is important because familial
HPS is treated most eﬀectively with allogenic bone marrow
transplantation, while treatment of underlying infection will
likely result in the resolution of IAHS [10]. While oﬃcial
guidelines regarding the infectious workup for HPS do not
exist, we conducted a series of tests that covered many of
the diseases with which HPS has been associated, including
bacterial, viral, and fungal pathogens.
3.2. Teaching Points of the Case. The key educational points
from this case involve not infection itself, but rather
infectious mimicry, the concept that a noninfectious disease
can present with signs typically seen in infection, thereby
encouraging the medical team to pursue a workup that
does not reveal the primary disease process. Issues regarding
infectious mimicry arose at both of the key diagnostic steps
in this case: ﬁrst, with the identiﬁcation of HPS (and not
sepsis) as the syndrome exhibited by the patient, second, as
the etiology of the HPS, once identiﬁed, was pursued.
Point 1: Systemic Inﬂammation Characterizes Both HPS and
Widespread Infectious Processes. The ﬁrst diagnostic step in
our case was the recognition that our patient was experi-
encing HPS and not only a systemic inﬂammatory response
associated with sepsis or viral infection. Regardless of the
primary cause, HPS itself is characterized by the same
systemic inﬂammation as a widespread infectious process [8,
10]. Because both bacterial sepsis and systemic illness with
a number of viral pathogens (Epstein-Barr virus, cytome-
galovirus, viral hepatitis, and the human immunodeﬁciency
virus) can display widespread inﬂammation, a physician
mightpursueaninfectiousdiagnosisandfailtorecognizethe
presence of HPS in the ﬁrst place. In our patient, we pursued
adiagnosisofsepsisanddidnotconsiderthepresenceofHPS
until multiple infectious disease evaluations were negative,
and we began to investigate noninfectious conditions.
The pursuit of a nonexistent systemic bacterial or viral
infection in this case delayed the identiﬁcation of HPS in the
patient and thus delayed the investigation for the primary
causeofHPS.Inourcase,thepatient’spresentationappeared
consistent with progression of a dental abscess to severe
sepsis, and this is the diagnosis that was pursued during his
previoushospitaladmissions.Itwasonlyaftermultiplefailed
treatmentsforpresumedinfectionatoutsideinstitutionsthat
the patient was referred to our tertiary care facility, and even
then, it was still thought that the patient was displaying signs
consistent with systemic infection. Physicians must therefore
be aware of HPS as a syndrome characterized by many
of the same ﬁndings as widespread infection and consider
this as a possibility when the infectious workup produces4 Case Reports in Medicine
Table 1: Comparison of the present case with previously published cases of ALCL-associated hemophagocytic syndrome.
Present case Krenova et al. [11] Sovinz et al. [12] Sevilla et al. [13] Cho et al. [14]
Age, gender 20 years, M 17 years, F 15 years, M 16 years, F 5 years, F 25 years, M
History and physical exam
FUO, facial
swelling, LAD,
and uveitis
FUO, LAD, and
splenomegaly
FUO, neck
swelling, and
splenomegaly
FUO,
splenomegaly
FUO,
abdominal pain,
and headache
FUO, myalgia,
weakness,
jaundice, LAD,
and
splenomegaly
Labs
WBC (cells/L) 2.0 × 109 —5 . 0 × 109 1.4 × 109 5.2 × 109 1.6 × 109
ANC (cells/L) 0.7 × 109 0.4 × 109 —— — —
Hemoglobin (g/dL) 9.5 4.4 10.1 7 8.9 8.8
Platelets (cells/L) 145 × 103 46 × 103 167 × 103 84 × 103 213 × 103 88 × 109
Triglycerides (mg/dL) 284 316 218 — — 113
Fibrinogen (mg/dL) 246 70 210 320 91 150
Ferritin (ng/mL) 13500 20 (g/L) 9270 5166 — 2240
Imaging studies
Soft tissue
swelling,
splenomegaly, fat
stranding, and
lung nodules
— Cervical LAD
Mediastinal
LAD,
splenomegaly,
and lung
nodules
Splenomegaly,
mediastinal and
hilar LAD
Cervical,
mediastinal, and
abdominal LAD,
hepatomegaly,
and
splenomegaly
Initial diagnosis IAHS Hepatitis IAHS IAHS IAHS ALCL
Biopsy
Lymph node — ALCL HPS; ALCL ALCL ALCL ALCL
Soft tissue Necrosis, HPS — — — —
Bone marrow HPS HPS; ALCL HPS HPS HPS HPS
Lung nodule Nonspeciﬁc — — ALCL — —
Final diagnosis ALCL ALCL ALCL ALCL ALCL ALCL
Abbreviations: M: male; F: female; FUO: fever of unknown origin; LAD: lymphadenopathy; WBC: white blood cells; ANC: absolute neutrophil count; ALCL:
anaplastic large cell lymphoma; HPS: hemophagocytic syndrome; IAHS: infection-associated hemophagocytic syndrome.
an unexpectedly negative result, especially when that result
persists and the patient fails to improve with appropriate
treatment for sepsis.
Point 2: Once HPS Is Identiﬁed, Inability to Identify a Non-
infectious Primary Cause Does Not Guarantee an Infectious
Primary Cause. Infectious mimicry is similarly problem-
atic once HPS has been identiﬁed. The physician caring
for a patient with HPS faces a considerable diagnostic
dilemma with regard to the search for underlying pro-
cesses. Our patient’s disease presented with signs of sepsis
and widespread systemic inﬂammation including cytope-
nia, pancreatitis, hepatitis, lung consolidations, and pleural
eﬀusions. While the pulmonary nodules were suggestive of
malignancy and would be unlikely to occur in IAHS, the
nondiagnostic tissue biopsies, as well as negative bone mar-
row, cell marker studies, and T-cell receptor rearrangement
studies shifted our focus away from a malignant primary
cause. We therefore defaulted once again to the pursuit
of an infectious primary cause because the noninfectious
investigations did not yield a malignant or rheumatologic
etiology.
The fulminant course prevented the diagnosis of the
underlying malignancy and resulted in the pursuit of an
infectious cause that did not exist. It is important for
physicians to recognize in these cases that absence of clear
evidence for noninfectious etiologies of HPS should not
result in an assumption of an infectious cause. Moreover,
absence of infection should encourage further noninfectious
workup. The investigation of a diagnostic pathway should
not be suspended until an underlying etiology has been
clearly identiﬁed.
3.3. HPS and ALCL. The etiology of HPS in this case
ultimately proved to be ALCL. It has been demonstrated
that ALCL is characterized by a high incidence (>50%
of patients) of systemic symptoms at presentation [15].
A histological variant of ALCL (“Linda Brown tumor”) is
characterized by extensive proliferation of phagocytosing
histiocytes accompanying the inﬁltrating tumor [16]. There
is evidence that ALCL secretes several proinﬂammatory
cytokines and chemokines [17], which are likely to be
responsible for inducing HPS.
HPS has been commonly associated with T-cell lym-
phoma [18], and according to one review, ALCL is the
dominant lymphoma in childhood leading to HPS, even
though it accounts for only 10–15% of childhood non-
Hodgkin’s lymphoma (NHL) [19]. In adults, however,Case Reports in Medicine 5
association with ALCL is rare [20]. Only a few published
cases discuss patients with ALCL who meet HLH-94 and
revised HLH-2004 criteria [11–14].
It is not uncommon for ALCL-associated HPS to be
confounded by an infectious presentation (Table 1). In three
cases [12, 13], initial workup suggested IAHS even though
an infectious agent could not be identiﬁed. In the fourth
[11],thepatientwasthoughttohaveviralhepatitis.Onecase
was identiﬁed as ALCL during the initial workup, and in this
case, the patient was successfully treated [14]. It is important
for clinicians to recognize that HPS, and especially ALCL-
associatedHPS,canpresentasandbemistakenforaprimary
infectious or infection-related process.
In each of the previous cases, tissue biopsy revealed
ALCL,andthediagnosiswasmadeintimetotreatthepatient
appropriately. It has been noted in one paper that ALCL-
associated HPS can include the type of lung ﬁndings
(mediastinal adenopathy, lung nodules) that were present
in our patient [13]; however, in these cases, the tissue
biopsy was diagnostic of ALCL, while in ours it was not.
In our case, many of the ﬁndings were too nonspeciﬁc to
facilitate a diagnosis of ALCL in time to be of beneﬁt to the
patient. The physical exam ﬁnding of painful, ﬁxed cervical
lymphadenopathy has been known to occur in ALCL but is
nonspeciﬁc to this condition. Similarly, the facial swelling
was characterized by nonspeciﬁc inﬂammatory features that
did not aid in the diagnosis of ALCL, even after autopsy. The
retroperitoneal fat stranding was determined to be due to
abdominalinvolvementonautopsybutagainwasconsidered
nonspeciﬁc during the imaging evaluations. While it has
been shown that the liver manifestations seen in our patient
can be a presenting manifestation of HPS [21, 22], these
ﬁndings are also nonspeciﬁc.
In this case, the majority of disease was in the gas-
trointestinal tract and surrounding tissues, a relatively rare
location for ALCL [23]. Due to our patient’s rapidly progres-
sive course and unremarkable malignancy workup, we were
unable to procure the necessary tissue specimens to correctly
diagnose the cause of HPS as ALCL before death.
4. Conclusion
The presentation of a patient with HPS represents a sig-
niﬁcant challenge for physicians conducting the diagnostic
workup. Infectious mimicry suggestive of sepsis and unre-
vealing studies for rheumatologic and malignant etiologies
may shift the diﬀerential toward infectious causes. While a
thorough infectious disease workup is essential, the rheuma-
tologic and neoplastic workup should not be suspended if an
infectious cause is not immediately obvious. Identiﬁcation
of the underlying etiology of HPS is crucial in order to
initiate timely and appropriate treatment and to avoid the
fatal outcome of the disease. It appears that HPS secondary
to ALCL tends to present with signs that may be mistaken
for evidence of infection. It is especially important for a
physician to consider this in challenging cases in which the
infectious workup is unrevealing.
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